The Impella platform integrates the trusted performance of the Impella CP heart pump with state-of-the-art SmartAssist technology. This next generation heart pump is designed to improve patient outcomes by using real-time intelligence to optimize positioning, managing and weaning of the Impella device for better patient care.

**Impella® Heart Pump**
Greater hemodynamic support and ease of use. Sensor technology allows for repositioning in the ICU without the need for imaging.*

**Advanced Pump Metrics**
Intelligent pump metrics on the Automated Impella Controller™ assist in positioning, managing and weaning the Impella device.

**Impella Connect®**
Cloud-based, remote monitoring of the Impella device status for collaborative patient management and better patient outcomes.

*For ventricularized pumps*
Impella CP with SmartAssist
Features to Improve Hemodynamic Support and Ease of Use

**Greater Hemodynamic Support**
Confident positioning allows for sustained higher flows.

- Peak flows up to 4.3 L/min

**Confident Positioning**
Hemodynamic sensors assist in managing and positioning Impella CP.

- Optical sensor senses aortic pressure
- Microaxial motor senses pressure difference between aorta and left ventricle

**Maintain Arterial Access**
Reaccess sheath allows for escalation of care and is designed to improve hemostasis.

- Allows access to the artery with up to a 0.035” guidewire
- 4 cm additional length

**Simplified Set-up**
Improve ease of use and faster set-up time.

- Reduction in set-up steps with fewer connections
- Single fluid line management in ICU

**Advanced Pump Metrics**
Designed to optimize pump management and assist in weaning

- Left-ventricular placement signal
- Displays Cardiac Power Output
- Displays trends of LVEDP and MAP to assist weaning
- 50% reduction in timing to resolve suction event

Cardiac Power Output: #1 Correlation to Mortality in AMI Cardiogenic Shock

\[ \text{CPO (in watts)} = \frac{(\text{MAP} \times \text{Cardiac Output})}{451} \]

1. Fincke, et. al. JACC, 2004 SHOCK TRIAL  
2. Abiomed Data on File ES 2019 -129

*Metrics only available with Impella Catheters with SmartAssist Technology.*
**Impella CP with SmartAssist Heart Pump Specifications**

<table>
<thead>
<tr>
<th>PART NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>0048-0003</td>
<td>Impella heart pump, 9 Fr catheter, 6 Fr pigtail, 14 Fr microaxial pump, Percutaneous insertion through the femoral artery</td>
</tr>
<tr>
<td>0043-0003</td>
<td>Impella Controller Purge Cassettes, Box of 5</td>
</tr>
<tr>
<td>0052-3046</td>
<td>14Fr Combo Introducer Kit containing 13cm and 25cm length sheaths</td>
</tr>
<tr>
<td>0052-3005</td>
<td>0.018” x 260 cm PTFE Guidewire for Impella 2.5 and Impella CP</td>
</tr>
</tbody>
</table>

**Maximum Flow:** 4.3 L/min  
**Maximum Mean:** 3.7 L/min  
**Speed Range:** 0 to 46,000 rpm  
**Interventional Length:** 92-98cm

**High-Risk PCI**
The Impella 2.5”, Impella CP”, and Impella CP” with SmartAssist™ Systems are temporary (≤ 6 hours) ventricular support devices indicated for use during high-risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the Impella 2.5, Impella CP, and Impella CP with SmartAssist Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events.

**Cardiogenic Shock**
The Impella 2.5”, Impella CP”, Impella CP” with SmartAssist™, Impella 5.0”, Impella 5.5” with SmartAssist™ and Impella LD™ Catheters, in conjunction with the Automated Impella Controller™ (collectively, “Impella® System Therapy”), are temporary ventricular support devices intended for short term use (≤ 4 days for the Impella 2.5, Impella CP, and the Impella CP with SmartAssist, and ≤ 14 days for the Impella 5.0, Impella 5.5 with SmartAssist and Impella LD) and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (< 48 hours) following acute myocardial infarction or open heart surgery or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (including volume loading and use of pressors and inotropes, with or without ABP). The intent of Impella System Therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function.

**Emergency Use Authorization**
Impella Left Ventricular (LV) Support Systems (Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, and Impella 5.5 with SmartAssist) are authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0 and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients (i.e. patients in the intensive care unit) with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac decompensation from myocarditis while on V-V ECMO support. The Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella LV Support Systems have been authorized for the above emergency use by the FDA under an EUA. The Impella LV Support Systems have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-2(b)(1), unless the authorization is terminated or revoked sooner.

**Important Risk Information for Impella Devices**

**Contraindications**
The Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella 5.5 with SmartAssist and Impella LD are contraindicated for use with patients experiencing any of the following conditions: Mural thrombus in the left ventricle; Presence of a mechanical aortic valve or heart constrictive device; Aortic valve stenosis/calcification (equivalent to an orifice area of 0.6 cm² or less); Moderate to severe aortic insufficiency (echocardiographic assessment graded as ≥ +2); Severe peripheral arterial disease precluding placement of the Impella System; Significant right heart failure*; Combined cardiopulmonary resuscitation*; Presence of an Atrial or Ventricular Septal Defect (including post-infarct VSD)*; Left ventricular rupture*; Cardiac tamponade*

*This condition is a contraindication for the cardiogenic shock indication only.

**Potential Adverse Events**
Acute renal dysfunction, Aortic valve injury, Bleeding, Cardiogenic shock, Cerebral vascular accident/Stroke, Death, Hemolysis, Limb ischemia, Myocardial infarction, Renal failure, Thrombocytopenia and Vascular injury

**Impella Connect™ Intended Use**
Impella Connect™ transfers a video image of the screen on the Automated Impella Controller™ to an authorized remote user. The transmitted image can be viewed by authorized remote users. The users can include the hospital’s clinicians, Abiomed local support staff, and Clinical Support Center (CSC) team members.

**Precautions**
• Impella Connect is not intended to provide real-time information for monitoring patient status on the Automated Impella Controller.
• During use of the Impella Connect, there will be a delay between when an image appears on the controller screen and when it is displayed at a remote viewing location.
• The Impella Connect is not a source of patient alarms, nor is its use intended as a replacement for monitoring the controller’s alarms.
• During use of the Impella Connect, receipt of the displayed controller information is not confirmed by the Automated Impella Controller, nor is the delivery of the displayed controller information to the authorized remote users guaranteed.
• The Impella Connect is not designed for use during transport.
• Radiated and conducted electromagnetic interference can affect the performance of the Impella Connect, causing a temporary loss of connectivity. To clear interference, either increase the distance between system components and the EMI source or turn off the EMI source. Any electromagnetic interference related to the Impella Connect will have no impact on any of the controller functional specifications.
• Portable and mobile RF communications equipment can affect medical electrical equipment.

In addition to the risks above, there are other WARNINGS and PRECAUTIONS associated with Impella devices. Visit [http://www.abiomed.com/important-safety-information](http://www.abiomed.com/important-safety-information) to learn more.